Physician profile
Mark A Mallory
NPI 1336116888
$4,154.53
in general payments reported to CMS, 2019-2025
26 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $21.82 · 2021: $152 · 2022: $198 · 2023: $990 · 2024: $1,124 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,535.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,635.07 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.66 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $324.84 | 2023-2025 | Dupixent |
| Celgene Corporation | $254.54 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $223.95 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $196.69 | 2019-2024 | Ocaliva |
| Lilly USA, LLC | $145.83 | 2023-2025 | Omvoh |
| Genzyme Corporation | $145.55 | 2023-2025 | |
| Ardelyx, INC. | $114.04 | 2023-2025 | Ibsrela |
| Pfizer INC. | $99.70 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $95.83 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $87.52 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Biotech, INC. | $60.75 | 2023-2025 | Stelara, Tremfya, Remicade |
| Aimmune Therapeutics, INC. | $57.11 | 2025 | Vowst, Zenpep |
| Celltrion USA INC. | $50.30 | 2025 | Vegzelma |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $49.44 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $46.75 | 2025 | Terlivaz |
| Qol Medical, LLC | $39.97 | 2019-2025 | Sucraid |
| Organon LLC | $27.77 | 2024 | |
| Pharmacosmos Therapeutics INC. | $18.68 | 2023 | Monoferric |
| Braintree Laboratories, INC. | $16.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.34 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $14.82 | 2022 | |
| Digestive Care, INC. | $14.45 | 2024 | Pertzye |
| Cook Medical LLC | $13.77 | 2023 | Instinct |
| Boston Scientific Corporation | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mallory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.